Clinical trial ALIDHE
A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with mIDH1 acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy
| Cancers | |
|---|---|
| Organ | Blood |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Servier |
| EudraCT Identifier | 2022-501709-11-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05907057 |
| Inclusion criteria | A single arm, open-label Phase 3b study to describe the safety andtolerability of ivosidenib in combination with azacitidine in adultpatients newly diagnosed with IDH1m acute myeloid leukemia (AML)ineligible for intensive induction chemotherapy |
| Last update |